Drug Trial Radar · NCT05725018
A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated Patients
Last checked: Nov 19, 2026Latest source record: Jun 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Apr 2, 2023
Primary completion
Sep 30, 2025
Study completion Sep 30, 2025
Sponsor
- Lead sponsor
- Abeona Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate and further characterize the safety of EB-101 (LZRSE-Col7A1 gene-corrected keratinocyte sheets with type VII collagen \[C7\] expression) for the treatment of large, chronic DEB wounds in new and previously EB-101 treated patients 12 months and older.
Conditions
- Epidermolysis Bullosa
- Recessive Dystrophic Epidermolysis Bullosa
- RDEB
Interventions
EB-101 Surgical application of RDEB woundsBiological
EB-101 autologous RDEB keratinocytes isolated from skin biopsies and transduced with a recombinant retrovirus containing a full-length COL7A1 expression cassette for C7 Other Names: • LZRSE-Col7A1 Engineered Autologous Epidermal Sheets \[LEAES\]
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Endpoint (number of treatment-related and treatment-emergent adverse events (AEs) and serious adverse events (SAEs)Time frame: 6 months
- Safety Endpoint (number of patients and wounds that have an infection or any related adverse event.)Time frame: 6 months
- Safety Endpoint (number of patients and wounds that result in hospitalization (serious adverse event )Time frame: 6 months
- Safety Endpoint (Incidence of squamous cell carcinoma)Time frame: 6 months
- Safety Endpoint RCR statusTime frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Stanford University
Redwood City, California
University of Massachusetts Medical School
Worcester, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.